Dechra
Libromide 325 mg for dogs 500 tablets

Helps in the control of refractory cases of epilepsy in dogs

Prescription required* (Exceptions apply)

Libromide 325 mg is a plain white circular biconvex 9.5 mm tablet with a single scored line on one face. This product is an anti-epileptic agent for use as an adjunct to phenobarbital in the control of refractory cases of epilepsy in dogs.

One Libromide 325 mg tablet contains:

Active substance:

  • Potassium bromide 325 mg

Excipients:

  • Lactose monohydrate
  • Microcrystalline cellulose
  • Magnesium stearate
  • Stearic acid
  • Saccharin sodium

Libromide 325 mg:

  • Must no be used in cases of known hypersensitivity to bromide, or to any of the excipients.
  • Must no be used in cases in dogs with severe renal insufficiency.

Libromide 325 mg posology:

  • For oral use. Administer with food.
  • Administer to dogs with refractory epilepsy, where seizure control is unsatisfactory despite appropriate phenobarbital therapy, when serum phenobarbital concentrations are at a steady-state within the therapeutic range.
  • The dose should be titrated to the individual dog as the required dosage will depend on the nature and severity of the underlying disease.
  • Administer with food at an initial dose of 15 mg/kg bodyweight twice daily(equivalent to a total daily dose of 30 mg/kg). Twice daily administration is advised in order to reduce the risk of gastrointestinal disturbances.
  • Due to the 24 day half-life of bromide, it can take several weeks or months to achieve steady-state serum concentrations. For at least the first three months following commencement of therapy, measure serum bromide concentrations every 4 weeks. The expected therapeutic serum bromide concentration (when used in conjunction with phenobarbital) is 800 to 2000 μg/ml. Adjustments to the dose should be made with regard to the frequency of seizures, the half-life of bromide and the serum bromide concentration. Long term monitoring of serum bromide (and associated phenobarbital) concentrations should be performed as clinically justified by the individual case.
  • Close monitoring for side effects is advisable at higher serum bromide concentrations.
  • Use in dogs with a body weight of less than 11 kg should be subject to a risk/benefit assessment, see section 4.5 of the pdf.

Libromide 325 mg is a plain white circular biconvex 9.5 mm tablet with a single scored line on one face. This product is an anti-epileptic agent for use as an adjunct to phenobarbital in the control of refractory cases of epilepsy in dogs.

One Libromide 325 mg tablet contains:

Active substance:

  • Potassium bromide 325 mg

Excipients:

  • Lactose monohydrate
  • Microcrystalline cellulose
  • Magnesium stearate
  • Stearic acid
  • Saccharin sodium

Libromide 325 mg:

  • Must no be used in cases of known hypersensitivity to bromide, or to any of the excipients.
  • Must no be used in cases in dogs with severe renal insufficiency.

Libromide 325 mg posology:

  • For oral use. Administer with food.
  • Administer to dogs with refractory epilepsy, where seizure control is unsatisfactory despite appropriate phenobarbital therapy, when serum phenobarbital concentrations are at a steady-state within the therapeutic range.
  • The dose should be titrated to the individual dog as the required dosage will depend on the nature and severity of the underlying disease.
  • Administer with food at an initial dose of 15 mg/kg bodyweight twice daily(equivalent to a total daily dose of 30 mg/kg). Twice daily administration is advised in order to reduce the risk of gastrointestinal disturbances.
  • Due to the 24 day half-life of bromide, it can take several weeks or months to achieve steady-state serum concentrations. For at least the first three months following commencement of therapy, measure serum bromide concentrations every 4 weeks. The expected therapeutic serum bromide concentration (when used in conjunction with phenobarbital) is 800 to 2000 μg/ml. Adjustments to the dose should be made with regard to the frequency of seizures, the half-life of bromide and the serum bromide concentration. Long term monitoring of serum bromide (and associated phenobarbital) concentrations should be performed as clinically justified by the individual case.
  • Close monitoring for side effects is advisable at higher serum bromide concentrations.
  • Use in dogs with a body weight of less than 11 kg should be subject to a risk/benefit assessment, see section 4.5 of the pdf.
119.70
Order within 20h 41m 57s (before 12AM)
And receive your order
on Wednesday 22 August
AIR FREIGHT

Customers who buy this product, usually buy: